Literature DB >> 18619558

Display scaffolds: protein engineering for novel therapeutics.

Stewart D Nuttall1, Renae B Walsh.   

Abstract

Protein scaffolds represent a new generation of universal binding frameworks for use as future immunopharmaceuticals to complement the expanding repertoire of therapeutic monoclonal antibodies. Here, we review recent literature describing advances in protein scaffold development, including efforts to engineer the minimal immunoglobulin-based binding-domain and molecular library design. Several diverse protein folds are currently under development on the basis of modular construction, a strategy also observed in families of naturally evolved immune receptors. We describe potential therapeutic and intracellular applications where scaffold-specific features provide distinct advantages for targeting of non-conventional antigens and comment on the scientific progress and validation of several designed scaffolds in the voyage towards first-in-human trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619558     DOI: 10.1016/j.coph.2008.06.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  15 in total

1.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

3.  Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging.

Authors:  Alain P Pecking; Dominique Bellet; Jean Louis Alberini
Journal:  Clin Exp Metastasis       Date:  2012-07-04       Impact factor: 5.150

Review 4.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

5.  N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance.

Authors:  Rui Gong; Yanping Wang; Tianlei Ying; Yang Feng; Emily Streaker; Ponraj Prabakaran; Dimiter S Dimitrov
Journal:  Mol Pharm       Date:  2013-05-29       Impact factor: 4.939

6.  Structure-based rational design of a Toll-like receptor 4 (TLR4) decoy receptor with high binding affinity for a target protein.

Authors:  Jieun Han; Hyun Jung Kim; Sang-Chul Lee; Seungpyo Hong; Keunwan Park; Young Ho Jeon; Dongsup Kim; Hae-Kap Cheong; Hak-Sung Kim
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

7.  Structural insights and biomedical potential of IgNAR scaffolds from sharks.

Authors:  Stefan Zielonka; Martin Empting; Julius Grzeschik; Doreen Könning; Caroline J Barelle; Harald Kolmar
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  Grand Challenges in Synthetic Biology to be Accomplished.

Authors:  Pengcheng Fu
Journal:  Front Bioeng Biotechnol       Date:  2013-06-12

Review 9.  Overview of Antibody Drug Delivery.

Authors:  Sahar Awwad; Ukrit Angkawinitwong
Journal:  Pharmaceutics       Date:  2018-07-04       Impact factor: 6.321

10.  Crystal structure of a Thermus aquaticus diversity-generating retroelement variable protein.

Authors:  Sumit Handa; Kharissa L Shaw; Partho Ghosh
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.